Traditional electrical stimulators implanted in biological tissues have largely relied on wired connections or bulky batteries, impeding patient mobility and often necessitating additional surgeries for device removal. Bioresorbable devices emerged as a solution to these challenges by safely degrading in the body over time, eliminating the risks associated with permanent implants. However, these earlier systems primarily delivered monophasic pulses, limiting therapeutic precision and adaptability in complex treatments. The innovation reported by Kim, Seo, Wang, and colleagues introduces a new paradigm by integrating wireless power transfer via NIR light and programmable waveform control within a fully bioresorbable platform, thus extending the functional range and easing the clinical management of bioelectronic therapies.

Central to this system is the incorporation of bioresorbable silicon phototransistors engineered to serve as optoelectronic modulators within the electrical circuitry. When illuminated by externally applied near-infrared light that penetrates deep into biological tissues, these phototransistors effectively adjust current flows at critical circuit nodes. This optical modulation capability replaces conventional electronic control elements, which often rely on persistent power sources or invasive wiring, thereby enabling the device to operate autonomously while still allowing fine-tuning of stimulation parameters through non-contact optical inputs.

The adoption of near-infrared light as the wireless power and control mechanism is particularly significant. NIR light possesses the ability to penetrate through several centimeters of tissue without causing damage, providing a safe and efficient transmission channel between the external controller and the implanted device. This feature supports programmability in situ, empowering clinicians to tailor electrical stimulation waveforms dynamically after device implantation. Precisely controlling the shape, amplitude, and timing of the electrical pulses is crucial for optimizing therapeutic outcomes in applications such as neuroregeneration and cardiac pacing.

The research team demonstrated the remarkable versatility of their bioresorbable system by successfully delivering a variety of stimulation waveforms. Monophasic pulses, which are unidirectional current flows, serve as a baseline therapy. More complex biphasic and polyphasic waveforms, which alternate current direction and comprise multiple phases respectively, have been shown to minimize tissue damage and improve efficacy in various biosignaling contexts. The ability to generate these sophisticated patterns expands the therapeutic range of the device, potentially enabling treatments that were previously inaccessible using bioresorbable technologies.

In demonstrating practical utility, the device was tested in both small and large animal models, validating its capacity for clinically relevant electrical stimulation regimes. The system was effectively employed in single- and dual-chamber cardiac pacing, a critical intervention for managing arrhythmias and heart block. Through controlled electrical stimulation, the device could synchronize cardiac contractions, a feat crucial for restoring efficient cardiac output. These trials highlight the translational potential of the technology for future human applications, situating it as a promising alternative to current electronic pacemakers that require permanent implantation and battery replacements.

Further extending the functional scope, the researchers utilized the bioresorbable stimulator to activate phrenic neuromuscular pathways to either induce or block diaphragmatic movements. The phrenic nerve controls diaphragmatic excursion, essential for respiration, and its modulation has significant implications for respiratory therapies, such as in patients with spinal cord injuries or central hypoventilation syndromes. By enabling wireless, programmable neurostimulation of the phrenic nerve, the technology offers a minimally invasive approach to manage life-sustaining respiratory functions, with the added benefit of device degradation after the therapeutic window.

The bioresorbable nature of the silicon phototransistors and associated electronics assures that after fulfilling their therapeutic role, the devices gradually dissolve into biocompatible byproducts. This process circumvents the complications related to device explantation surgeries, reducing patient risk and healthcare costs. Moreover, the materials chosen minimize inflammatory responses and tissue irritation, facilitating seamless integration with host biology during the operational phase.

The engineering behind this system represents an intersection of materials science, optoelectronics, and biomedical engineering. The architecture leverages the semiconducting properties of silicon in thin-film, bioresorbable form, combined with circuit design optimized for minimal power consumption and maximal efficiency during NIR irradiation. These multidisciplinary innovations collectively overcome longstanding barriers in the fabrication of transient electronic implants capable of sophisticated programmable functionality.

Controlling the stimulation waveforms via light permits remote adjustment without physical connections, paving the way for real-time therapeutic modulation responsive to patient status or physiological signals. Future iterations could incorporate feedback mechanisms by integrating bioresorbable sensors that monitor tissue response, creating closed-loop systems for personalized medicine. This dynamic adaptability could be transformative in managing chronic conditions requiring variable and responsive electrical stimulation protocols.

This research also addresses one of the fundamental challenges of implantable devices: power delivery. The optical wireless power transfer circumvents the need for bulky batteries or explant procedures, offering renewed device miniaturization potential. Coupled with programmable phototransistors, these innovations enable multifunctional implants that conform to soft tissues and degrade harmlessly, a trifecta crucial for implantation in sensitive organs like the heart and nervous system.

The ability to deliver polyphasic waveforms through a single bioresorbable receiver unit is particularly noteworthy. Conventionally, generating these complex waveforms requires sophisticated circuitry and stable power sources, neither of which are trivial to implement in resorbable devices. The research showcases how optical control unlocks this capability without sacrificing bioresorbability or wireless operation, representing a paradigm shift in transient biomedical electronics.

The successful application of this device in large animal cardiac models bridges a critical gap toward clinical translation. Such models replicate human physiological scales and complexities far more closely than small animals, validating both the efficacy and safety of the system under conditions analogous to human therapies. This demonstration is an essential milestone on the path toward human clinical trials and eventual regulatory approval.

Moreover, the phrenic nerve stimulation experiments illustrate the broader applicability beyond cardiac pacing. Neuromuscular control via electrical stimulation has vast clinical relevance, from restoring motor function to modulating organ systems. The biodegradable, wireless nature of this system makes it especially suited for temporary therapeutic interventions, such as post-surgical recovery or transient disease states, where permanent implants would be unnecessary or undesirable.

While this work represents a major leap forward, ongoing challenges remain, including further optimization of device longevity relative to treatment durations, refinement of light delivery systems to maximize tissue penetration and minimize off-target effects, and integration with advanced biocompatible materials to tailor resorption timelines. Addressing these will be key to broadening the range of clinical applications and ensuring patient safety across diverse scenarios.

Overall, this wirelessly powered, light-controlled, bioresorbable stimulation system emerges as a versatile platform poised to transform bioelectronic therapies. Its elegant combination of programmable polyphasic waveform delivery, wireless operation via near-infrared light, and full bioresorbability addresses critical limitations of current implantable stimulators. By enabling sophisticated, minimally invasive, and transient electrical stimulation paradigms, this technology advances the frontiers of regenerative medicine, cardiac therapy, and neuromodulation, marking a significant milestone in the evolution of biomedical devices.

Subject of Research: Wireless bioresorbable electrical stimulation device with programmable waveform control using near-infrared light

Article Title: A wirelessly powered, light-controlled, bioresorbable stimulation system with programmable polyphasic waveforms

Article References:
Kim, J.U., Seo, S.G., Wang, H. et al. A wirelessly powered, light-controlled, bioresorbable stimulation system with programmable polyphasic waveforms. Nat Electron (2026). https://doi.org/10.1038/s41928-026-01655-8

Image Credits: AI Generated

DOI: https://doi.org/10.1038/s41928-026-01655-8

A groundbreaking study led by DU Xuemin at the Shenzhen Institutes of Advanced Technology (SIAT) of the Chinese Academy of Sciences, recently published in Advanced Materials, introduces a novel fully integrated bioelectronic system designed for long-term, biosafe vagus nerve modulation. This multifunctional ferroelectric bioelectronic interface (FBI) leverages cutting-edge materials science and bioengineering to realize adaptive nerve interfacing that combines mechanical compliance, strong bioadhesion, and biomimetic electrophysiology.

Fundamental to this new approach is the FBI device’s unique three-layer composite architecture. The foundational substrate comprises a bilayer hydrogel synthesized from natural polysaccharides—specifically chitosan and chemically functionalized alginate. This hydrogel possesses intelligent self-rolling capabilities; upon exposure to aqueous environments, it transforms autonomously into a tubular structure. This feature enables the device to snugly conform around nerves as small as approximately 0.5 millimeters in diameter, ensuring intimate and stable contact without causing mechanical trauma.

The interface between the device and the nerve tissue is further enhanced by the chemical functionalization of the alginate, which introduces groups capable of forming both hydrogen and covalent bonds with the biological substrate. Such strong, sutureless adhesion addresses a critical limitation of earlier implant designs which often required invasive fixation methods that could damage delicate neural structures or provoke local inflammation.

Overlaying this hydrogel substrate is a layer composed of ferroelectric polymer composites. This layer consists of alternating stripes of poly(vinylidene fluoride-co-trifluoroethylene) (P(VDF-TrFE)) integrated with carbon nanotube (CNT) networks. The ferroelectric properties of P(VDF-TrFE) enable dipole switching under external stimulation, especially when illuminated by near-infrared (NIR) light. This dipole switching dynamically generates electrical signals that closely mimic the temporal and spatial characteristics of natural neuronal action potentials. The integration of CNTs improves electrical conductivity and mechanical robustness, enabling precise electrical stimulation while maintaining structural integrity.

A pivotal breakthrough lies in the FBI’s remote activation capability via NIR light. Unlike traditional electrical stimulators that require wired connections or battery-powered systems, this device can be triggered non-invasively. The NIR-triggered dipole switching within the ferroelectric polymer generates controlled bioelectrical signals that interface seamlessly with neural tissue, promoting efficient neuromodulation without physically intrusive hardware.

Compared to conventional silicon-based optoelectronic materials that are often cytotoxic and prone to generating harmful reactive oxygen species (ROS), the FBI device demonstrates remarkable biocompatibility. Quantitative assessments revealed a 16-fold reduction in ROS production, underscoring its suitability for chronic implantation without inducing oxidative stress or secondary tissue damage.

In rigorous in vivo studies using freely moving rat models, the FBI device exhibited outstanding long-term performance. After 60 days of continuous implantation, there was no detectable displacement of the device, no evidence of nerve compression, and no signs of local inflammatory response or fibrosis. Moreover, the anti-inflammatory effects mediated by vagus nerve stimulation were sustained throughout the implantation period, cementing its functional durability.

The FBI platform’s unique amalgamation of precise geometric adaptability, seamless bioadhesive fixation, biomimetic bioelectrical signaling, and superior biosafety heralds a new paradigm for implantable bioelectronics. By addressing the longstanding challenges of long-term nerve interface stability and safety, it sets a benchmark for next-generation neural modulatory therapies.

This technology opens promising avenues beyond autoimmune disease management, with far-reaching implications for treating a variety of neurological disorders where precise, adaptive nerve stimulation is beneficial. The remote, wireless operation combined with structural compliance offers patient-friendly solutions that minimize surgical complications and improve quality of life.

Ultimately, these advances reflect a significant stride in bioelectronic medicine—merging materials science, neurobiology, and engineering to realize robust, life-long interfaces between devices and the nervous system. The FBI device underscores a future where neural interfaces are not only effective but intimately integrated and harmonized with the living tissue, transforming therapeutic possibilities across medical disciplines.

As research continues to optimize these bioelectronic interfaces, the blend of ferroelectric polymers and biomimetic design principles promises to revolutionize the landscape of implantable medical devices, moving closer toward seamless human-machine symbiosis for health restoration and enhancement.

Subject of Research: Development of multifunctional ferroelectric bioelectronic interfaces for long-term vagus nerve modulation and autoimmune disease treatment.

Article Title: Multifunctional Ferroelectric Bioelectronic Interfaces for Long-term Biosafe Vagus Nerve Modulation.

News Publication Date: Information not provided.

Web References: https://advanced.onlinelibrary.wiley.com/doi/10.1002/adma.73023

References: Information not provided.

Image Credits: Information not provided.

Keywords

Vagus nerve stimulation, ferroelectric bioelectronics, autoimmune disease therapy, implantable neural interfaces, poly(vinylidene fluoride-co-trifluoroethylene), carbon nanotubes, hydrogel bioadhesion, biomimetic electrical signals, near-infrared activation, reactive oxygen species reduction, long-term biosafety, neuroinflammation control.